Boston Scientific Corp. said Tuesday it's launching a clinical trial to study a new type of drug-coated stent.---A MONTH ? old news..
The device, dubbed Synergy, features a biodegradable coating and aims to address some concerns associated with earlier generations of drug-coated stents.
Stents are tiny mesh tubes used to prop open clogged arteries. Some versions of the devices are coated with drugs that help prevent the formation of scar tissue. However, there is some evidence that drug-coated stents increase the risk that a patient will develop dangerous clots.
Boston Scientific's Synergy stent differs from earlier technologies, as the coating degrades over time, leaving behind a bare-metal stent.
The clinical trial will test the product on 291 patents in Australia, Europe and New Zealand.
Boston Scientific (NYSE: BSX) is based in Natick, Mass., but has major operations in Arden Hills and Maple Grove. It develops and manufactures stents in Minnesota.
Read more: Boston Scientific to study new stent - Minneapolis / St. Paul Business Journal
Market Data 
Markets 
AI
